Viewing Study NCT04629703


Ignite Creation Date: 2025-12-24 @ 7:11 PM
Ignite Modification Date: 2025-12-27 @ 5:50 PM
Study NCT ID: NCT04629703
Status: COMPLETED
Last Update Posted: 2023-08-18
First Post: 2020-11-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Sponsor: Rigel Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module